Skip to content
thestock.space

As of 6 Nov 2026, Venmax Drugs and Pharmaceuticals trades at 33.9× trailing earnings, above the industry P/E of 28.7×, and the shares are 56% below their 52-week high. Net profit grew 3.2% a year over 3 years; its ROCE of 2.0% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt. It is a small-cap company with a market cap of ₹16 Cr, ranked 144th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 48% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹14.49
Day high
₹14.49
Day low
₹13.01
Prev. close
₹14.23
Volume
771

Health check

1 good · 5 to check
  • ReturnsBehind

    −47.8% over a year, better than 0 of 7 peers.

  • Price tagPricier

    P/E 33.9 vs industry 28.7.

  • GrowthSlow

    Profit +3.2% a year over 3 years.

  • ProfitabilityWeak

    ROCE 2.0% vs peer median 17.9%.

  • Balance sheetSolid

    Practically debt-free, Piotroski 6 of 9.

  • Red flags2 to check

    Return on equity is low at 3.4%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹16 Cr, #144 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹9 Cr · profit ₹0 Cr
Market cap
₹16 Cr
Small cap
P/E
33.9
Industry 28.7
Price to book
1.08
Peers 4.99
Dividend yield
0.00%
ROE
3.4%
Peers 14.7%
ROCE
2.0%
Peers 17.9%
Debt to equity
0.01
Debt ₹0.21 Cr
EPS (TTM)
₹0.41
OPM (TTM)
1.6%
Net margin 3.5%
Sales growth
+104.9%
Latest quarter vs a year ago
Profit growth
+211.8%
Latest quarter vs a year ago
Price to sales
1.73
EV/EBITDA 78.2

Strengths and risks

Strengths

  • Practically debt-free.
  • Quarterly profit up 211.8% on a year ago.
  • Quarterly sales up 104.9% on a year ago.

Risks to check

  • Return on equity is low at 3.4%.
  • 56% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Venmax Drugs and Pharmaceuticals

Venmax Drugs and Pharmaceuticals Limited engages in the business of pharmaceutical products, drug intermediaries, and API's in India. The company was formerly known as Yenkey Drugs & Pharmaceuticals Ltd and changed its name to Venmax Drugs and Pharmaceuticals Limited in April 2009. Venmax Drugs and Pharmaceuticals Limited was incorporated in 1988 and is based in Hyderabad, India.

Headquarters
Hyderabad
Employees
2
Sector
Healthcare
ISIN
INE154G01022
Website
venmaxdrugs.com

Price range

52 weeks

₹12.51₹31.49

Today

₹13.01₹14.49
Avg volume (3M)
8.6K
1-year return
minus 47.8%
From 52-week high
minus 55.9%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
VENMAXVenmax Drugs and Pharmaceuticals13.90minus 2.32%1633.91.082.0%3.4%1.6%–3.2%0.00%minus 47.8%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
1.21.31.63.92.5
1.21.31.63.92.4
00−000.1
3.2%3.5%−1.6%0.3%4.7%
000.10.10
00–––
00000
0000.10.1
–46.0%25.2%−2.7%0.1%
0000.10.1
0.070.050.050.200.10

Profit & loss

Yearly, ₹ crore
Profit CAGR 3Y
+3.2%
EPS CAGR 3Y
−21.2%
ROE
3.4%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
––0.88
––1.97.9
−0.2−0.1−1.10.1
––−131.4%1.5%
0.40.21.10.2
0000
––−0–
0.20.1−00.3
0.0%25.7%25.5%10.4%
0.20.1−00.2
–minus 71.4%minus 116.3%–
0.430.12-0.020.21

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
5.25.25.211.6
−6−5.9−0.82.5
0.40.400.3
0.60.40.71.8
0.20.15.216.2
0.1000
002.58.6
0.202.67.6
0.20.15.216.2

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
−00−2.3−11
0–4.89.7
–02.5−1.3
−00−2.3−11

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you